Dr. Amanda Sokan was recognized for her work in translational medicine that focuses on aging research, curriculum development and public health policy.

Antibody tests, groundbreaking research and community outreach are a few of the ways the University of Arizona Health Sciences met the test of a pandemic.

A UArizona Health Sciences public health student and a microbiology student in Canada won a science competition with an Instagram account to refute bad science.

Antibody tests, groundbreaking research and community outreach are a few of the ways the University of Arizona Health Sciences met the test of a pandemic.

Dr. Anthony S. Fauci and several epidemiologists and health and science writers for The New York Times discuss their predictions about the months ahead. "I won't take traveling to my extended family for granted," said Alicia Allen, PhD, MPH, an assistant professor of clinical translational sciences at the University of Arizona College of Medicine – Tucson.

An encouraging new study at the University of Arizona could lead to new immunotherapy treatments for Type-1 diabetes and could be extended to other autoimmune diseases. The study involves genetically engineered T-cells that can seek out and destroy pathogens in the pancreas. The research was led by Michael Kuhns, an associate professor of immunobiology in the UArizona College of Medicine - Tucson.

The coronavirus has upended almost all aspects of life this year, and that includes the holiday giving and volunteering that credit unions traditionally do. Kelly Reynolds, a professor and environmental microbiologist at the University of Arizona Mel and Enid Zuckerman College of Public Health, is interviewed.

Dr. Sam Keim, a professor of emergency medicine at the University of Arizona College of Medicine - Tucson, is interviewed about his experiences as a clinical trial participant in Moderna's COVID-19 vaccine

A team at the University of Arizona Health Sciences found that SARS-CoV-2 antibodies provide lasting immunity. This finding suggested that those who had survived an infection and those who received a vaccine for COVID-19 would be immune from reinfection for several months.

Sandra Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the challenges for advanced practitioners treating patients with hematologic malignancies who are at high risk for COVID-19 infection.